特朗普的开创性指令引发 Enveric Biosciences 股价飙升超过 160%

Table of Contents Shares of psychedelic biotechnology companies surged Monday following President Trump’s weekend executive order directing federal health authorities to accelerate review timelines for psychedelic-based medical treatments. Enveric Biosciences (ENVB) dominated the rally, closing the trading day with gains exceeding 160% — a remarkable performance for a company carrying a market capitalization of merely $3.43 million. Enveric Biosciences, Inc., ENVB 该行政命令采取了全行业范围的方法，而不是针对特定公司。它代表了 FDA 和附属监管机构的全面授权，以简化迷幻疗法的审批途径。事实证明，这一公告足以推动几乎所有公开交易的迷幻生物技术股票走高。 AtaiBeckley (ATAI) 在盘前交易中飙升 28.1%。 Compass Pathways (CMPS) 上涨 26.1%。 Definium Therapeutics (DFTX) 上涨 14.6%。 GH Research (GHRS) 上涨 19.7%。看涨势头渗透到整个行业。 In addition to the regulatory directive, President Trump announced a $50 million funding allocation specifically for ibogaine research initiatives. Ibogaine represents a psychoactive substance extracted from African plant sources and remains classified as Schedule I under U.S. federal law — designating it as having no accepted medical applications. The funding commitment represents a notable policy pivot regarding mental health treatment approaches, particularly concerning post-traumatic stress disorder. Preliminary research has demonstrated ibogaine’s potential therapeutic benefits for PTSD sufferers, with particular promise for military veteran populations. Compass Pathways CEO Kabir Nath publicly praised the executive action, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” Brian Abrahams, an analyst at RBC, supported this assessment, characterizing the directive as “a substantial step towards diminishing regulatory risk” facing psychedelic therapeutic development. ENVB价格的大幅上涨是在一个重要的背景下发生的。 The company had recently completed a $5 million private placement just days prior — a capital raise that actually exceeded the firm’s total market capitalization at that time. The financing involved selling 2,222,223 shares priced at $2.25 apiece, accompanied by two separate warrant series carrying a $2.00 per share exercise price. The company’s primary development candidate, designated EB-003, targets both 5-HT2A and 5-HT1B receptor systems and is undergoing development for various psychiatric and neurological indications. Recently disclosed mechanistic studies demonstrated that EB-003 activates dual signaling mechanisms associated with antidepressant and anxiolytic therapeutic effects. ENVB has also secured U.S. patent protection encompassing its EVM301 molecular compounds, which include the EB-003 candidate, alongside Canadian trademark approvals for five brand marks including “Enveric” and “Next Generation Mental Health.” Should investors exercise both warrant series issued through the private placement fully, the company stands to receive approximately $8.9 million in additional gross capital. Monday’s stock movement — surpassing 160% — captured both the favorable regulatory tailwind generated by the executive order and the strategic timing of recent fundraising activities that extended the company’s operational runway precisely when this catalytic policy shift materialized.